Curto A, Albaladejo A, Alvarado A. Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran. J Clin Exp Dent. 2017;9(2):e289-93.

 

 

doi:10.4317/jced.53219

http://dx.doi.org/doi:10.4317/jced.53219

 

References

1. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S-325S.

PMid: 22315265 PMCid: 3278063

 

2. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. The Evolving Consensus. Antithrombotic therapy in Atrial Fibrillation. Chest. 1998;114:579-89.
https://doi.org/10.1378/chest.114.5_Supplement.579S

PMid: 9822064

 

3. Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016;204:88-94.
https://doi.org/10.1016/j.ijcard.2015.11.084
PMid:26655548

 

4. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.
https://doi.org/10.1016/S0140-6736(10)61194-4

PMid: 20801496

 

5. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669-76.
https://doi.org/10.1161/CIRCULATIONAHA.111.055970
PMid:22215856

 

6. Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, et al. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. Am J Cardiol. 2014;114:849-55.
https://doi.org/10.1016/j.amjcard.2014.06.015
PMid:25103918

 

7. Huntington JA, Baglin TP. Targeting thrombin--rational drug design from natural mechanisms. Trends Pharmacol Sci. 2003;24:589-95.
https://doi.org/10.1016/j.tips.2003.09.002
PMid:14607082

 

8. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-99.
https://doi.org/10.1124/dmd.107.019083
PMid:18006647

 

9. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
https://doi.org/10.2165/0003088-200948010-00001
PMid:19071881

 

10. Hu TY, Vaidya VR, Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016;12:35-44.
PMid:26937198 PMCid:PMC4762436

 

11. van Leent MW, Stevanović J, Jansman FG, Beinema MJ, Brouwers JR, Postma MJ. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data. PLoS One. 2015;10:e0135054.
https://doi.org/10.1371/journal.pone.0135054
PMid:26241880 PMCid:PMC4524689

 

12. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost. 2011;106:868-76.
https://doi.org/10.1160/TH11-05-0358
PMid:21946939

 

13. Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2015;2015:117-24.
https://doi.org/10.1182/asheducation-2015.1.117
PMid:26637710

 

14. Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47:1635-40.
https://doi.org/10.1177/1060028013509074
PMid:24259624

 

15. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46:1627-36.
https://doi.org/10.1345/aph.1R179
PMid:23232017

 

16. Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137:572-4.
https://doi.org/10.1309/AJCPAU7OQM0SRPZQ
PMid:22431533

 

17. Perry DJ, Noakes TJ, Helliwell PS; British Dental Society. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203:389-93.
https://doi.org/10.1038/bdj.2007.892
PMid:17934422

 

18. O'Connell JE, Stassen LF. New oral anticoagulants and their implications for dental patients. J Ir Dent Assoc. 2014;60:137-43.
PMid:25080640

 

19. Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, Baird MF, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56:823-31.
https://doi.org/10.1053/j.ajkd.2010.05.023
PMid:20709439 PMCid:PMC2963672

 

20. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343-8.
https://doi.org/10.1161/CIRCULATIONAHA.111.090464
PMid:22700854

 

21. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
https://doi.org/10.1056/NEJMoa0905561
PMid:19717844

 

22. Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Dis. 2016;22:23-32.
https://doi.org/10.1111/odi.12371
PMid:26386350

 

23. Johnston S. A New Generation of Antiplatelet, and Anticoagulant Medication and the Implications for the Dental Surgeon. Dent Update. 2015;42:840-2.
PMid:26749792

 

24. Scott A, Gibson J, Crighton A. The management of dental patients taking new generation oral anticoagulants. Prim Dent J. 2014;3:54-8.
https://doi.org/10.1308/205016814813877289
PMid:25668377

 

25. Tsolka P. Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. Arrhythm Electrophysiol Rev. 2014;3:85-9.
https://doi.org/10.15420/aer.2014.3.2.85
PMid:26835072 PMCid:PMC4711592

 

26. Hong CH, Islam I. Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry. J Blood Disorders Transf. 2013;4:166.
https://doi.org/10.4172/2155-9864.1000166

 

27. van Diermen DE, van der Waal I, Hoogstraten J. Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:709-16.
https://doi.org/10.1016/j.oooo.2013.07.026
PMid:24120910

 

28. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective pro-cedure or surgery. Blood. 2012;120:2954-62.
https://doi.org/10.1182/blood-2012-06-415943
PMid:22932800

 

29. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111:4871-9.
https://doi.org/10.1182/blood-2007-10-120543
PMid:18309033

 

30. Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 2014;59:296-301.
https://doi.org/10.1111/adj.12199
PMid:24889878

 

31. Curtin C, Hayes JM, Hayes J. Dental implications of new oral anticoagulants for atrial fibrillation. Dent Update. 2014;41:526-8,530-1.
PMid:25195485

 

32. Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results from a large, multicentre, prospective, case–control study. Thromb Haemost. 2010;104:972-5.
https://doi.org/10.1160/TH10-02-0139
PMid:20806110

 

33. Breik O, Tadros R, Devitt P. Thrombin inhibitors: surgical considerations and pharmacology. ANZ J Surg. 2013;83:215-21.
https://doi.org/10.1111/ans.12078
PMid:23384088

 

34. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27.
https://doi.org/10.1160/TH09-11-0758
PMid:20352166

 

35. Crowther MA, Warkentin TE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost. 2009;7:107-10.
https://doi.org/10.1111/j.1538-7836.2009.03429.x
PMid:19630780

 

36. Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013;79:d74.
PMid:23920075

 

37. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72.
https://doi.org/10.1161/CIRCULATIONAHA.110.004747
PMid:21576658

 

38. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303.
https://doi.org/10.1111/j.1365-2125.2007.02899.x
PMid:17506785 PMCid:PMC2000643

 

39. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:431-41.
https://doi.org/10.1016/j.oooo.2011.10.005
PMid:22668425

 

40. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436-50.
https://doi.org/10.1161/CIRCULATIONAHA.110.004424
PMid:21464059